NASDAQ:BLRX - BioLineRx Ltd.
$0.41
 $0.00
+0.86%
2:15PM EDT
2019-02-15
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  BLRX     avg for
industry  
  avg for
sector  
42 stocks weight:  12. 91   0. 00   0. 00  
42 stocks rank:  3. 85 K 1. 86 K 1. 09 K
# analyst opinions:  4. 00   14. 92   14. 43  

quick ratio:  7. 28   5. 37   1. 81  
current ratio:  7. 53   5. 69   2. 19  

target price low:  0. 30   88. 97   117. 82  
target price avg:  0. 40   115. 19   141. 96  
target price high:  0. 64   143. 40   163. 16  
1-yr high:  1. 45   124. 30   142. 77  
last close:  0. 41   101. 85   127. 84  
50-day avg:  0. 55   98. 27   122. 46  
200-day avg:  0. 82   99. 72   122. 70  
1-yr low:  0. 40   78. 19   100. 16  
volume:  2. 46 M 2. 38 M 4. 64 M
50-day avg volume:  1. 12 M 3. 31 M 4. 94 M
200-day avg volume:  834. 52 K 3. 23 M 4. 28 M

1-day return:  0. 00 % 0. 22 % 0. 48 %
this week return:  2. 50 % 1. 77 % 2. 01 %
12-wk return:  -36. 92 % 6. 56 % 3. 33 %
52-wk return:  -58. 24 % -2. 23 % 14. 35 %

enterprise value (EV):  9. 28 M 55. 17 B 104. 51 B
market cap:  48. 41 M 49. 01 B 96. 46 B
EBITDA:  -25. 79 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -0. 36   -91. 79   2. 29  
total debt:  179. 00 K 13. 73 B 16. 57 B
debt/equity:  0. 44   258. 01   110. 73  
net income (common):  -24. 67 M 2. 37 B 3. 58 B

shares outstanding:  108. 08 M 607. 99 M 1. 22 B
shares:  79. 12 M 605. 53 M 1. 15 B
shares short:  1. 27 M 11. 62 M 12. 55 M
shares short prior month:  1. 35 M 11. 95 M 13. 44 M
short ratio:  2. 84   4. 82   3. 10  
total cash/share:  0. 32   12. 02   11. 46  
total cash:  35. 00 M 7. 41 B 7. 37 B
free cash flow:  -16. 04 M 95. 99 M 2. 04 B
operating cash flow:  -25. 38 M 164. 74 M 3. 04 B

book value:  0. 38   14. 43   28. 26  
price/book:  1. 09   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -39. 73 % --- ---
1-yr mean volatility:  -0. 20 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 23   3. 03   4. 09  
forward EPS:  -0. 15   4. 33   6. 99  
P/E:  -1. 77   6. 11   26. 91  
forward P/E:  -2. 67   8. 38   10. 48  
PE/G:  0. 06   0. 37   5. 61  
growth:  -27. 49 % 683. 72 % 104. 79 %
earnings high:  -0. 06   1. 27   1. 66  
earnings avg:  -0. 09   1. 01   1. 53  
earnings low:  -0. 19   0. 76   1. 40  
revenue high:  150. 00 K 2. 86 B 11. 19 B
revenue avg:  40. 00 K 2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -29. 17 % -3. 27 % 3. 81 %
return on equity:  -49. 53 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  0. 21   1. 21   0. 93  
sharpe (1yr):  -0. 66   0. 06   0. 98  

held % insiders:  4. 29 % 6. 46 % 3. 21 %
held % institutions:  35. 31 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : BLRX
.    + 0.408 =         0.408 :: INITIAL WEIGHT
.  + 370.784 =       371.192 :: inverse volume-to-price addition
.  + 283.252 =       654.444 :: spline projection addition
.  - 173.131 =       481.313 :: poor performance penalty
.    x 0.643 =       309.579 :: one-year gains+dividend factor
.    x 2.649 =       820.059 :: 13 weeks' performance factor
.    x 1.492 =      1223.929 :: industry recommendation factor
.    x 0.997 =      1220.359 :: return on assets factor
.    x 0.995 =      1214.315 :: return on equity factor
.    x 2.677 =       3250.42 :: current ratio factor
.    x 1.077 =      3499.771 :: quick ratio factor
.    x 1.163 =      4069.546 :: short ratio factor
.    x 2.011 =      8183.587 :: price-to-book factor
.    x 1.001 =      8190.577 :: debt-to-equity factor
.    x 2.166 =     17741.039 :: P/E weight
.    x 1.986 =     35233.643 :: PE/G factor
.    x 1.496 =     52719.803 :: beta factor
.    x 0.656 =     34586.141 :: sharpe factor
.    x 0.948 =     32794.683 :: target low factor
.    x 0.972 =     31886.891 :: target mean factor
.    x 1.074 =      34257.55 :: target high factor
.    x 1.066 =     36505.285 :: industry 12-weeks return
.    x 0.989 =     36117.112 :: overall "drift" factor
.    x 0.998 =     36040.793 :: largest single-day jump factor
.     x 0.06 =      2149.123 :: low price factor
.      x 1.0 =      2149.267 :: factor hist industry gain for week 06
.   cubeRoot =        12.905 :: reduced for readability
.                     12.905 :: FINAL WEIGHT for NASDAQ:BLRX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org